학술논문
Burosumab resulted in better clinical outcomes than continuation with conventional therapy in both younger (1-4 years-old) and older (5-12 years-old) children with X-linked hypophosphatemia
Document Type
ConferencePaper
Author
Source
HORMONE RESEARCH IN PAEDIATRICS. 91:71-72
Subject
Language
English
English
English
ISSN
1663-2818